LAG3 and colorectal carcinoma: Overall, there was a lack of compelling evidence of clinical activity in PD-(L)1-naïve advanced or metastatic MSS CRC, supporting the need to further evaluate biomarkers predictive of response to anti-LAG-3 therapies and novel immunotherapies to improve outcomes in this patient population with high medical need.